



**HAL**  
open science

## Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease

Dongbing Lai, Babak Alipanahi, Pierre Fontanillas, Tae-hwi Schwantes-an, Jan Aasly, Roy N Alcalay, Gary W Beecham, Daniela Berg, Susan Bressman, Alexis Brice, et al.

► **To cite this version:**

Dongbing Lai, Babak Alipanahi, Pierre Fontanillas, Tae-hwi Schwantes-an, Jan Aasly, et al.. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease. *Annals of Neurology*, 2021, 90 (1), pp.76 - 88. 10.1002/ana.26094 . hal-04538877

**HAL Id: hal-04538877**

**<https://hal.sorbonne-universite.fr/hal-04538877>**

Submitted on 9 Apr 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# Genomewide Association Studies of *LRRK2* Modifiers of Parkinson's Disease

Dongbing Lai, PhD <sup>1†</sup> Babak Alipanahi, PhD,<sup>2,3†</sup> Pierre Fontanillas, PhD,<sup>2†</sup> Tae-Hwi Schwantes-An, PhD,<sup>1</sup> Jan Aasly, MD, PhD,<sup>4</sup> Roy N. Alcalay, MD, MS,<sup>5</sup> Gary W. Beecham, PhD,<sup>6</sup> Daniela Berg, MD,<sup>7,8</sup> Susan Bressman, MD,<sup>9</sup> Alexis Brice, MD,<sup>10</sup> Kathrin Brockman, MD <sup>8,11</sup> Lorraine Clark, PhD,<sup>12</sup> Mark Cookson, PhD,<sup>13</sup> Sayantan Das, PhD,<sup>2</sup> Vivianna Van Deerlin, MD, PhD,<sup>14</sup> Jordan Follett, PhD,<sup>15</sup> Matthew J. Farrer, PhD,<sup>15</sup> Joanne Trinh, PhD,<sup>16</sup> Thomas Gasser, MD,<sup>8,11</sup> Stefano Goldwurm, MD, PhD,<sup>17</sup> Emil Gustavsson, PhD,<sup>18</sup> Christine Klein, MD <sup>16</sup> Anthony E. Lang, MD,<sup>19</sup> J. William Langston, MD,<sup>20</sup> Jeanne Latourelle, DSc,<sup>21</sup> Timothy Lynch, MD,<sup>22</sup> Karen Marder, MD, MPH,<sup>23</sup> Connie Marras, MD, PhD,<sup>19</sup> Eden R. Martin, PhD,<sup>6</sup> Cory Y. McLean, PhD,<sup>2,24</sup> Helen Mejia-Santana, MS,<sup>25</sup> Eric Molho, MD,<sup>26</sup> Richard H. Myers, PhD,<sup>27</sup> Karen Nuytemans, PhD,<sup>6</sup> Laurie Ozelius, PhD,<sup>9</sup> Haydeh Payami, PhD,<sup>28</sup> Deborah Raymond, MS,<sup>9</sup> Ekaterina Rogaeva, PhD,<sup>29</sup> Michael P. Rogers, MD,<sup>30</sup> Owen A. Ross, PhD <sup>31,32</sup> Ali Samii, MD,<sup>33</sup> Rachel Saunders-Pullman, MD,<sup>9</sup> Birgitt Schüle, MD,<sup>34</sup> Claudia Schulte, MS,<sup>8,11</sup> William K. Scott, PhD,<sup>6</sup> Caroline Tanner, MD,<sup>35</sup> Eduardo Tolosa, MD, PhD,<sup>36</sup> James E. Tomkins, PhD,<sup>37</sup> Dolores Vilas, MD,<sup>36</sup> John Q. Trojanowski, MD, PhD,<sup>14</sup> The 23andMe Research Team,<sup>2</sup> Ryan Uitti, MD,<sup>38</sup> Jeffery M. Vance, MD, PhD,<sup>6</sup> Naomi P. Visanji, PhD <sup>19</sup> Zbigniew K. Wszolek, MD,<sup>38</sup> Cyrus P. Zabetian, MD, MS <sup>33</sup> Anat Mirelman, PhD <sup>39</sup> Nir Giladi, MD,<sup>39</sup> Avi Orr-Urtreger, PhD,<sup>39</sup> Paul Cannon, PhD,<sup>2</sup> Brian Fiske, PhD,<sup>40</sup> and Tatiana Foroud, PhD<sup>1</sup>

**Objective:** The aim of this study was to search for genes/variants that modify the effect of *LRRK2* mutations in terms of penetrance and age-at-onset of Parkinson's disease.

**Methods:** We performed the first genomewide association study of penetrance and age-at-onset of Parkinson's disease in *LRRK2* mutation carriers (776 cases and 1,103 non-cases at their last evaluation). Cox proportional hazard models and linear mixed models were used to identify modifiers of penetrance and age-at-onset of *LRRK2* mutations, respectively. We also investigated whether a polygenic risk score derived from a published genomewide association study of Parkinson's disease was able to explain variability in penetrance and age-at-onset in *LRRK2* mutation carriers.

**Results:** A variant located in the intronic region of *CORO1C* on chromosome 12 (rs77395454;  $p$  value =  $2.5E-08$ , beta = 1.27, SE = 0.23, risk allele: C) met genomewide significance for the penetrance model. Co-immunoprecipitation

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com). DOI: 10.1002/ana.26094

Received Apr 7, 2020, and in revised form Apr 28, 2021. Accepted for publication Apr 29, 2021.

Address correspondence to Dr Lai, Department of Medical and Molecular Genetics, Indiana University School of Medicine, 410 W. 10th Street, HS 4000, HITS, Indianapolis, IN 46202-3002. E-mail: [dlai@iu.edu](mailto:dlai@iu.edu)

<sup>†</sup>These authors contributed equally to this work.

analyses of *LRRK2* and *CORO1C* supported an interaction between these 2 proteins. A region on chromosome 3, within a previously reported linkage peak for Parkinson's disease susceptibility, showed suggestive associations in both models (penetrance top variant:  $p$  value =  $1.1E-07$ ; age-at-onset top variant:  $p$  value =  $9.3E-07$ ). A polygenic risk score derived from publicly available Parkinson's disease summary statistics was a significant predictor of penetrance, but not of age-at-onset.

**Interpretation:** This study suggests that variants within or near *CORO1C* may modify the penetrance of *LRRK2* mutations. In addition, common Parkinson's disease associated variants collectively increase the penetrance of *LRRK2* mutations.

ANN NEUROL 2021;90:76–88

Parkinson's disease (PD) is the second most common neurodegenerative disease in older adults.<sup>1</sup> Several genes showing autosomal dominant (*SNCA*, *LRRK2*, and *VPS35*) or recessive (*PRKN*, *PINK1*, and *DJ-1*) inheritance patterns have been identified as the cause of familial PD. These genes harbor rare, high penetrance mutations that explain up to 10% of familial PD cases in different populations.<sup>1,2</sup> Recently, large genomewide association studies (GWAS) have identified over 90 loci with small individual effects on disease risk in both familial and sporadic PD.<sup>3,4</sup>

Mutations in *LRRK2* are among the most common genetic causes of PD.<sup>1,2</sup> The most frequent mutation is G2019S (rs34637584), which explains up to 10% of familial PD cases and 1% to 2% of all PD cases.<sup>2,5</sup> Among patients with PD, the frequency of the G2019S mutation is approximately 3% in Europeans, 16% to 19% in Ashkenazi Jews and up to 42% in Arab-Berbers.<sup>6–15</sup> Estimates of the risk for developing PD among *LRRK2* G2019S mutation carriers range from 15% to 85%.<sup>16–19</sup> To explain the incomplete penetrance

of G2019S, it has long been hypothesized that there are other genes/variants outside of *LRRK2* acting to modify its effect (*LRRK2* modifiers). Identification of *LRRK2* modifiers could aid the development of novel prevention and treatment strategies for PD.

Most studies of *LRRK2* modifiers, to date, have focused on candidate genes. Because the protein product of *LRRK2* may interact with  $\alpha$ -synuclein (encoded by *SNCA*), and tau (encoded by *MAPT*),<sup>20,21</sup> variants in *SNCA* and *MAPT* were widely investigated. However, the results have been inconsistent, possibly due to small sample sizes and differences in variants and populations investigated.<sup>22–30</sup> Other PD associated genes, such as *GBA*,<sup>29</sup> *BST1*,<sup>29</sup> *GAK*,<sup>30</sup> and *PARK16*<sup>29,31,32</sup> have also been investigated. However, the number of studies is limited and findings remain to be replicated. Genomewide searches for *LRRK2* modifiers are sparse and limited to linkage studies. Using 85 *LRRK2* carriers from 38 families, a genomewide linkage study of *LRRK2* modifiers found a suggestive linkage region at 1q32 (limit of detection [LOD] = 2.43); but that study did not identify any candidate genes/

From the <sup>1</sup>Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN; <sup>2</sup>23andMe, Inc., Sunnyvale, CA; <sup>3</sup>Google LLC, Palo Alto, CA; <sup>4</sup>Department of Neurology, St. Olavs Hospital, Trondheim, Norway; <sup>5</sup>Department of Neurology, Columbia University, New York, NY; <sup>6</sup>John P. Hussman Institute for Human Genomics and Dr. John T. Macdonald Department of Human Genetics, University of Miami, Miller School of Medicine, Miami, FL; <sup>7</sup>Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany; <sup>8</sup>Department of Neurodegenerative Diseases, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany; <sup>9</sup>Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY; <sup>10</sup>Sorbonne Université, Institut du Cerveau et de la Moelle épinière (ICM), AP-HP, Inserm, CNRS, University Hospital Pitié-Salpêtrière, Paris, France; <sup>11</sup>German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; <sup>12</sup>Department of Pathology and Cell Biology, Columbia University, New York, NY; <sup>13</sup>Laboratory of Neurogenetics, National Institute of Aging, National Institute of Health, Bethesda, MD; <sup>14</sup>Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, PA; <sup>15</sup>Laboratory of Neurogenetics and Neuroscience, Fixel Institute for Neurological Diseases, McKnight Brain Institute, L5-101D, UF Clinical and Translational Science Institute, University of Florida, Gainesville, FL; <sup>16</sup>Institute of Neurogenetics, University of Luebeck, Luebeck, Germany; <sup>17</sup>Parkinson Institute, ASST “G.Pini-CTO, Milan, Italy; <sup>18</sup>Centre for Applied Neurogenetics, University of British Columbia, Vancouver, Canada; <sup>19</sup>The Edmond J. Safra Program in Parkinson's Disease and the Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospital, Toronto, Canada; <sup>20</sup>Departments of Neurology, Neuroscience, and Pathology, Stanford University School of Medicine, Stanford, CA; <sup>21</sup>GNS Healthcare, Cambridge, MA; <sup>22</sup>Dublin Neurological Institute at the Mater Misericordiae University Hospital, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland; <sup>23</sup>Department of Neurology and Psychiatry, Taub Institute and Sergievsky Center, Columbia University Vagelos College of Physicians and Surgeons, New York, NY; <sup>24</sup>Google LLC, Cambridge, MA; <sup>25</sup>Gertrude H. Sergievsky Center, Columbia University, New York, NY; <sup>26</sup>Department of Neurology, Albany Medical College, Albany, NY; <sup>27</sup>Department of Neurology, Boston University, Boston, MA; <sup>28</sup>Department of Neurology, University of Alabama at Birmingham, Birmingham, AL; <sup>29</sup>Tanz Centre for Research in Neurodegenerative Diseases and Department of Neurology, University of Toronto, Toronto, Canada; <sup>30</sup>Department of General Surgery, University of South Florida Morsani College of Medicine, Tampa, FL; <sup>31</sup>Departments of Neuroscience and Clinical Genomics, Mayo Clinic, Jacksonville, FL; <sup>32</sup>School of Medicine and Medical Science, University College Dublin, Dublin, Ireland; <sup>33</sup>VA Puget Sound Health Care System and Department of Neurology, University of Washington, Seattle, WA; <sup>34</sup>Department of Pathology, Stanford University School of Medicine, Stanford, CA; <sup>35</sup>University of California, San Francisco Veterans Affairs Health Care System, San Francisco, CA; <sup>36</sup>Parkinson Disease and Movement Disorders Unit, Hospital Clinic Universitari, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona (UB), Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), Barcelona, Spain; <sup>37</sup>School of Pharmacy, University of Reading, Reading, UK; <sup>38</sup>Department of Neurology, Mayo Clinic, Jacksonville, FL; <sup>39</sup>Tel Aviv Sourasky Medical Center, Sackler Faculty of Medicine and Sagol School of Neuroscience, Tel Aviv University, Tel Aviv, Israel; and <sup>40</sup>The Michael J. Fox Foundation for Parkinson's Research, New York, NY

Additional supporting information can be found in the online version of this article.

variants underlying the linkage peak.<sup>33</sup> A genomewide linkage scan in Arab-Berber PD families found *DNM3* as a *LRRK2* modifier.<sup>34</sup> This finding was not independently replicated, although it was still significant in a meta-analysis including the participants reported in the original finding.<sup>25,35</sup> GWASs have successfully detected many disease genes/variants, including those associated with PD. However, to date, no GWAS for *LRRK2* modifiers has been reported, probably due to limitations in sample size and corresponding statistical power.

In this study, we recruited *LRRK2* mutation carriers from multiple centers and performed the first GWAS to identify genes/variants that modify the penetrance and age-at-onset of PD among *LRRK2* mutation carriers. Using the largest cohort to date, which consisted of 1,879 *LRRK2* mutation carriers (including 776 PD cases), one genomewide significant association signal was found in the intronic region of the *CORO1C* gene. Using co-immunoprecipitation analyses, we demonstrated that the protein product of *CORO1C* interacted with *LRRK2*. In addition, we found that a polygenic risk score (PRS) derived from publicly available PD GWAS summary statistics, was associated with penetrance, but not age-at-onset, of PD in *LRRK2* mutation carriers.

## Methods

### Study Participants

The studies and the *LRRK2* mutation carriers were grouped into 3 cohorts. The first cohort was primarily identified from The Michael J. Fox Foundation's *LRRK2* Consortium and consisted of research sites worldwide (referred to as the MJFF consortium cohort). We searched PubMed and identified study groups that reported *LRRK2* mutation carriers and then asked them to participate in this study (PubMed IDs: 16240353, 16333314, 18986508, and 16960813).<sup>36–39</sup> We also made announcements at international conferences to recruit more study mutation carriers. Details can be found in their publications.<sup>36–39</sup> To maximize participation and facilitate uniform data preparation across sites, a minimal dataset was submitted for all subjects that included *LRRK2* mutation status, sex, age-at-onset (for PD cases), age at last evaluation (for non-PD participants), and pedigree information, along with the availability of a minimal amount of DNA (approximately 2 ug). The minimal phenotypic data were sent to Indiana University and the subjects were assigned a unique identifier. The second cohort was from Tel Aviv University, Israel (referred to as the Israel cohort). Participants were of Ashkenazi origin and recruited from the Movement Disorders Unit at Tel Aviv Medical Center. PD diagnosis was confirmed by a

movement disorders specialist and clinical disease status (PD or not diagnosed as PD) was evaluated at the time of blood draw for genetic testing. The third cohort (referred to as the 23andMe cohort) consisted of research participants of the personal genetics company 23andMe, Inc. who were *LRRK2* G2019S carriers and whose PD status was known. Individuals who reported via an online survey that they had been diagnosed with PD by a medical professional, were asked to provide their age at diagnosis. For individuals who affirmed at least once that they had not been diagnosed with PD, their age at the most recent completion of the survey was recorded. The institutional review board at each participating site approved this study.

### Genotyping, Quality Review, and Imputation

All study participants were genotyped on the Illumina Omni 2.5 Exome Array version 1.1 (Illumina, San Diego, CA, USA), except 166 participants from the Israel cohort, who were genotyped on an earlier version of the same array (version 1.0). This array has common, rare, and exonic variants that were selected from diverse world population samples included in the 1000 Genomes Project. In total, there were > 2.58 M variants, including > 567 K exonic variants. Participants from the MJFF consortium and 23andMe were genotyped at the Center for Inherited Disease Research (CIDR) at Johns Hopkins University (Baltimore, MD, USA). The Israel cohort was genotyped at Tel Aviv University and 2 samples from the MJFF consortium were included for quality control. There were 134 duplicated and unexpected identical participants among all 3 cohorts. Pairwise concordance rates were all > 99.97%, showing high consistency among the 2 genotyping laboratories and the 2 versions of the Illumina array.

Variants with genotypic missing rates > 5% and nonpolymorphic variants were excluded. In addition, variants with A/T or C/G alleles were also excluded due to strand ambiguity. Hardy–Weinberg equilibrium (HWE) was not used to filter variants because these participants were ascertained to be *LRRK2* mutation carriers and this participant selection scheme would directly violate HWE and remove potential *LRRK2* modifiers from the analysis.

To confirm the reported pedigree structure and detect cryptic relatedness, we used a set of 56,184 high quality (missing rate < 2%, HWE  $p$  values > 0.001), common (minor allele frequency [MAF] > 0.1), and independent (linkage disequilibrium as measured by  $r^2$  < 0.5) variants to calculate the pairwise identity by descent using PLINK.<sup>40</sup> Reported pedigree structures were revised accordingly, if necessary. Mendelian error checking was performed in the revised pedigree structure. Any inconsistent genotypes were set to missing. The same set of variants

was also used to estimate the principal components (PCs) of population stratification using Eigenstrat.<sup>41</sup> All samples were imputed to the Haplotype Reference Consortium (<http://www.haplotype-reference-consortium.org/>) using Minimac3.<sup>42</sup> A total of 725,802 high quality genotyped variants were selected for imputation (MAF > 3%, HWE  $p$  value > 0.0001, and missing rate < 5%). EAGLE version 2.4<sup>43</sup> was used to phase genotyped variants for each sample. After filtering out variants with poor imputation quality score ( $R^2 < 0.6$ ) and checking for Mendelian inconsistencies using PLINK,<sup>40</sup> a final dataset of 7,934,276 imputed and genotyped variants was used for association analyses.

### Genomewide Association Studies

Our association analysis tested two models: (1) variants modifying the penetrance for PD among *LRRK2* mutation carriers (penetrance model), and (2) variants modifying the age-at-onset for PD among *LRRK2* mutation carriers (age-at-onset model). For the penetrance model (including PD cases and those not diagnosed as PD at last evaluation), the association analysis was designed to identify variants associated with the time to PD diagnosis or last evaluation for


undiagnosed mutation carriers. For the age-at-onset model (PD cases only), the association analysis tested whether variants contributed to the age-at-onset for PD cases among *LRRK2* mutation carriers.

For the penetrance model, a mixed effect Cox proportional hazard model (frailty model) was used with sex, 10 PCs, array, and cohort indicators as covariates. Family relationships were adjusted by using a kinship matrix calculated using R package COXME (<https://cran.r-project.org/web/packages/coxme/index.html>). For the age-at-onset model, a linear mixed model was fit with the same covariates as the penetrance model and a kinship matrix to adjust family relationships. Although adjusting 10 PCs and family relationships could minimize the effects of population stratifications and shared genetic and environment factors among family members, the use of this mixed samples was designed to search for common genetic variants that have the same effects in participants from all populations and could miss population-specific or family specific findings. Variants with MAF > 1% were tested for association in these 2 models. In addition to the single variant analyses, we performed gene-based association analyses for both the

**TABLE 1. Summary of Study Cohorts**

Cohorts	MJFF consortium	Israel	23andMe	Total
Number of participants	768	185	926	1,879
% PD cases (N)	67% (512)	66% (122)	15% (142)	41% (776)
% Females (N)	49% (378)	53% (98)	52% (480)	51% (956)
Mean age at last evaluation (SD) among non-PD	56.2 (15.8)	53.6 (14.3)	45.9 (17.3)	48.7 (17.4)
Mean age at PD diagnosis (SD) among cases	56.9 (12.2)	57.5 (11.4)	59.4 (10)	57.4 (11.7)
<i>LRRK2</i> mutation (% of total)				
<i>G2019S</i>	699 (91%)	185 (100%)	926 (100%)	1810 (96%)
<i>Non-G2019S</i>	69 (9%)	N/A	N/A	69 (4%)
Families				
Number of participants with families (% total)	473 (61%)	96 (52%)	284 (31%)	853 (45%)
Total number of families	138	38	118	294
Average (max) family size	3.4 (17)	2.5 (4)	2.4 (10)	2.9
Average PD ratio in families	0.56	0.43	0.12	0.37
Ancestries (% of total)				
European ancestry	91%	100%	89%	91%
<i>Ashkenazi Jewish</i>	37%	100%	48%	49%
African-American or Latinos ancestry	9%	0%	11%	9%

MJFF = Michael J. Fox Foundation; N/A = not applicable; PD = Parkinson's disease.



**FIGURE 1: Manhattan and Q-Q plots of single variant analysis of penetrance and age-at-onset models.** Y-axis is the  $-\log(p)$  value for associations. X-axis is physical position of the variants across the genome. The horizontal line indicates genome-wide significance. (A) Penetrance model; (B) age-at-onset model; and (C) Q-Q plots of penetrance model (left) and age-at-onset model (right).

penetrance and age-at-onset models. We focused on rare exonic and splicing variants, based on annotations from Variant Effect Predictor (<https://useast.ensembl.org/info/docs/>

[tools/vep/index.html](https://useast.ensembl.org/info/docs/)), and restricting to variants with MAF < 3%. Only genotyped variants ( $N = 725,802$ ) were used in the gene-based analyses due to the low quality of imputation for rare variants. The R package COXME was used to perform all analyses (<https://cran.r-project.org/web/packages/coxme/index.html>). Conditional analysis was conducted using the most significant variant in an associated region as a covariate, and additional signals within the associated region were determined based on  $p$  values < 0.01.

### Cell Culture, Co-Immunoprecipitation, and Antibodies

To test whether the protein product of the identified gene interacts with LRRK2, we performed co-immunoprecipitation analyses. HEK293FT (R70007; Invitrogen) cells were maintained as previously described<sup>44</sup> and transiently transfected with pEGFP-C1, pEGFP-CORO1C, or co-transfected with 3xFlag-LRRK2 using Lipofectamine 2000 (ThermoFisher Scientific) for 16 hours. Cells were washed once with ice cold PBS and lysed in 1 ml of GFP-trap buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.3% Triton X-100, 5% Glycerol, Halt phosphatase inhibitor cocktail [ThermoFisher Scientific], and protease inhibitor cocktail [Roche]) or Flag/GFP buffer (20 mM Tris-HCl pH 7.5, 300 mM NaCl, 1 mM EDTA, 50 mM NaF, 0.3% Triton X-100, 5% Glycerol, Halt phosphatase inhibitor cocktail [ThermoFisher Scientific], and protease inhibitor cocktail [Roche]) for 30 minutes on ice, followed by centrifugation at 4°C for 10 minutes at 13,900 g to obtain the supernatant. The supernatant was then incubated with either pre-equilibrated GFP-Trap agarose beads (ChromoTek) for 1 hour at 4°C on an end over end rotator to recover the GFP tag or pre-cleared with Pierce Protein A/G Agarose (ThermoFisher Scientific; 20 minutes at 4°C). Pre-cleared lysates were incubated with 1  $\mu$ g of monoclonal anti-flag antibody (F3165; Millipore-Sigma) or rabbit polyclonal anti-GFP (Ab290; Abcam) for 2 hours at 4°C on an end over end rotator. Antibody complexes were captured by Protein A/G Agarose beads for 2 hours. Bead complexes were washed 6 times with lysis buffer, followed by elution in 1 times loading dye containing 2%  $\beta$ -mercaptoethanol for 6 minutes at 95°C. All samples were resolved by Western blot as previously described.<sup>45</sup> Each co-immunoprecipitation was repeated in 2 to 3 independent experiments. Primary antibodies used in this study are as follows: mouse monoclonal anti-FLAG M2 (F3165) was purchased from ThermoFisher Scientific; Rabbit polyclonal to GFP was from Abcam (ab290), and anti-LRRK2 was from UC Davis/NIH NeuroMab Facility (clone N241A/34).

### In Silico Functional Studies

To evaluate whether the genomewide significant findings had immediate biological consequences on gene expression



**TABLE 2. Variants That Have P Values < 1.0E-6 in the Penetrance Model**

CHR	BP	rsid	Alleles	Gene	Annotation	MAF	BETA	SE	p value	G2019S only p value
1	221,173,137	rs141686162	A/G	<i>HLX, DUSP10</i>	Intergenic	0.01	0.42	0.28	0.13	0.86
3	124,083,400	rs145611031	C/G	<i>KALRN</i>	Intron	0.02	1.14	0.23	5.2E-07	2.3E-07
3	140,288,373	rs150382576	A/G	<i>CLSTN2</i>	3'UTR	0.02	0.78	0.22	5.3E-04	2.1E-03
3	152,841,926	rs59679443	A/G	<i>RAP2B, ARHGEF26</i>	Intergenic	0.04	0.62	0.17	3.1E-04	1.6E-04
3	152,932,435	rs16846845	G/C	<i>RAP2B, ARHGEF26</i>	Intergenic	0.05	0.83	0.16	1.1E-07	<b>4.5E-08</b>
4	160,854,320	rs12272007	A/G	<i>LOC107986324</i>	Intergenic	0.01	1.22	0.36	6.0E-04	1.9E-03
5	115,786,384	rs73781088	C/T	<i>SEMA6A</i>	Intron	0.03	0.47	0.19	0.01	0.05
8	9,520,115	rs28398294	G/A	<i>TNKS</i>	Intron	0.03	1.09	0.22	5.7E-07	1.1E-06
9	127,532,973	rs148922482	C/T	<i>NR6A1</i>	Intron	0.01	0.90	0.28	1.4E-03	3.7E-03
11	120,585,515	rs28470321	G/A	<i>GRIK4</i>	Intron	0.01	1.91	0.36	9.0E-08	6.1E-08
<b>12</b>	<b>109,080,567</b>	<b>rs77395454</b>	<b>C/T</b>	<b><i>CORO1C</i></b>	<b>Intron</b>	<b>0.02</b>	<b>1.27</b>	<b>0.23</b>	<b>2.5E-08</b>	<b>1.0E-06</b>
14	90,982,388	rs76788674	A/G	<i>CALM1, TTC7B</i>	Intergenic	0.03	0.78	0.16	7.1E-07	2.8E-06
X	123,652,525	rs185981774	A/G	<i>TENM1</i>	Intron	0.02	0.86	0.17	5.4E-07	3.9E-07

Note: Genomewide significant variant is in bold.

CHR = chromosome; MAF = minor allele frequency.

(expression quantitative trait locus [eQTL]) of nearby genes, we searched Open Targets Genetics (<https://genetics.opentargets.org/>) and GTEx (<https://www.gtexportal.org/>). In addition, protein-protein interaction (PPI) data were assessed to identify whether the protein product of the nominated gene either interacts directly with *LRRK2* or has common interactors that are shared with *LRRK2*, using Protein Interaction Network Online Tool (PINOT) version 1.0<sup>46</sup> queried on June 16, 2020 ([http://www.reading.ac.uk/bioinf/PINOT/PINOT\\_form.html](http://www.reading.ac.uk/bioinf/PINOT/PINOT_form.html)). We also performed chromatin interaction mapping to check whether our top findings interact with *LRRK2* distantly. Functional Mapping and Annotation of GenomeWide Association Studies (FUMA: <https://fuma.ctglab.nl/>) was used to perform chromatin interaction mapping.<sup>47</sup> Hi-C data for chromatin interaction mapping were from Schmitt et al 2016 and Giusti-Rodriguez et al 2019,<sup>48,49</sup> and are available in FUMA.


### Polygenic Risk Score Analyses

In the largest GWAS analysis of PD susceptibility to date, Nalls et al meta-analyzed 17 datasets with 56,306 PD cases or proxy-cases and 1.4 million controls.<sup>4</sup> Based on their results, they developed a PRS using summary

statistics of 1,805 variants that can explain 26% of PD heritability.<sup>4</sup> In this study, we performed PRS analysis using these 1,805 variants. Detailed information about how to select these 1,805 variants was described in Nalls et al.<sup>4</sup> Because we were searching for *LRRK2* modifiers, variants in the *LRRK2* region (chr12: 40,118,913-41,263,086) were excluded. The PRS was calculated as a weighted summation of effective alleles with the logarithm of odds ratios as the weights. This derived PRS was used to fit the same models with the same set of covariates as described for the genomewide association analyses using the R package COXME.

### Results

Study participants from the 3 cohorts are summarized in Table 1. In total, 1,879 participants (853 individuals from 294 families and 1,026 singletons) were included in the analyses. Among them, 776 had, or self-reported, a PD diagnosis and 1,103 were not classified as affected with PD at the last evaluation. The majority of participants were G2019S carriers, only 4% carried other *LRRK2* mutations as reported by the contributing sites, all from the MJFF consortium cohort. In the 23andMe cohort, 85% of participants were not diagnosed with PD and



**FIGURE 2:** Regional association plot of the chromosome 12 region for the penetrance model. Y-axis is the  $-\log_{10}(p\text{-value})$  for associations. X-axis denotes physical positions on the chromosome (Mb). The color scale shows the extent of linkage disequilibrium (LD; as measured by  $r^2$ ) between each variant and the top variant (indicated by the purple diamond) with larger  $r^2$  indicating greater LD. Peaks indicate the recombination hot spots. SNP = single nucleotide polymorphism.

most of them were less than 50 years of age at the time of their last evaluation. Based on PCs, the majority of participants were of European ancestry.


Manhattan plots for the single variant analyses of the penetrance and age-at-onset models are shown in Figure 1A and 1B. Q-Q plots for both models are shown in Figure 1C. No obvious bias was detected in either model; and genomic controls were 1.055 and 1.052 for the penetrance model and age-at-onset model, respectively. Twelve loci showed variants with  $p$  values  $< 1.0E-6$  (ie, meet the threshold for suggestive significance) in either the penetrance model or the age-at-onset model (Supplementary Table S1). One variant on chromosome 12 reached genomewide significance ( $rs77395454$ ,  $p$  value =  $2.5E-08$ ) in the penetrance model (Table 2, Supplementary Table S1). Conditional analysis suggested that there were no additional association signals in this locus. The top variant ( $rs77395454$ ) on the chromosome 12 region is located in an intron of *CORO1C* (coronin 1C; Fig 2). The causal haplotype(s) spanned *SELPLG*, *CORO1C*, and *SSH1*, with most of the variants within *CORO1C*. Figure 3A–C shows the survival curves stratified by  $rs77395454$  genotypes for all samples, familial samples, and unrelated samples, respectively. Heterozygous

$rs77395454$  carriers (20 familial and 37 unrelated samples) had an increased risk of PD. Six other loci met suggestive significance ( $p$  value  $< 1.0E-6$ ) for the penetrance model (see Table 2).

For the age-at-onset model, no chromosomal region reached genomewide significance, but 7 loci met the suggestive association threshold. Except for variants on chromosome 3 identified in both models,  $rs73781088$  on chromosome 5 (intron of *SEMA6A*) for the age-at-onset model and  $rs28398284$  on chromosome 8 (intron of *TNKS*) for the penetrance model, all other variants had no or marginal LD support. Variants on chromosome 3 from both models cover the same region but identified different haplotypes.

For comparison purposes, we also performed analyses limited to only the *LRRK2* G2019S carriers; overall the results were comparable (see Table 2, Supplementary Table S1) but  $rs16846845$  on chromosome 3 ( $p$  value =  $4.5E-08$ ) was genomewide significant for the penetrance model. In addition, we performed analyses using only individuals of predicted Ashkenazi Jewish ancestry. Results are less significant due to dramatically decreased sample sizes as shown in Supplementary Table S2. No genomewide






**FIGURE 3:** Cumulative incidence of PD stratified by *rs77395454* genotypes. Dashed lines indicate 95% confidence interval. Due to the low MAF of *rs77395454* and therefore the small number of CC genotype carriers, only participants with TT and CT genotypes are shown. (A) All samples; (B) familial samples; and (C) unrelated samples. MAF = minor allele frequency; SNP = single nucleotide polymorphism.

significant results were detected in the gene-based analysis using exonic variants for either model.

We next sought evidence of a physical interaction between *CORO1C* and *LRRK2* using co-immunoprecipitation analyses. GFP-tagged *CORO1C* or eGFP empty vector control were transfected into HEK293FT and lysates were incubated with anti-GFP agarose beads to recover the GFP tag; relative to empty vector control, eGFP-*CORO1C* co-precipitated endogenous *LRRK2* from HEK293FT cells (Fig 4A). To further support this interaction, 3xFlag-tagged *LRRK2* with either GFP-tagged *CORO1C* or eGFP empty vector control were cotransfected into HEK293FT and, after 16 hours, lysates were incubated with anti-GFP or anti-Flag antibodies to immunoprecipitate the GFP or Flag tag, respectively. Immunoprecipitation of *LRRK2* via the Flag antibody co-precipitated eGFP-*CORO1C*, but not the eGFP from the empty vector control. (Fig 4B). Reciprocally, immunoprecipitation of the GFP tag via a GFP antibody co-precipitated Flag-*LRRK2* only in the presence of GFP-*CORO1C* but not the empty vector GFP control (Fig 4C). Thus, co-immunoprecipitation analysis of Flag-*LRRK2* and GFP-*CORO1C* support an interaction between these 2 proteins.

By searching Open Targets Genetics and GTEx, we found that the most significant variant, *rs77395454*, is an eQTL of *CORO1C* in blood and *MYO1H* in visceral adipose (omentum) but not in any brain tissues. The minor allele (C allele) is associated with higher expression of *CORO1C* and *MYO1H*. We did not find any previous report that *LRRK2* interacts with *CORO1C* or *MYO1H* directly, however, there are several proteins that are the common interactors of both *LRRK2* and *CORO1C*: *ABCE1*, *ACTR2*, *CDC42*, *DAPK1*, *MYO1C*, *RAC1*, and *TP53*, as identified by using PINOT,<sup>46</sup> and it remains to be determined whether the interaction of *LRRK2* with *CORO1C* is within a single complex or dependent upon these common interacting proteins. Chromatin interaction mapping did not find any variant that interacts with *LRRK2* distantly.

Among those 1,805 variants that were obtained from the study of Nalls et al 2019,<sup>4</sup> 20 variants were not present in our datasets. An additional 27 variants were located in the *LRRK2* region and were excluded, and 1,758 variants were included in the PRS calculation. The PRS was a significant predictor in the penetrance model ( $p$  value =  $7.8E-4$ ) but not in the age-at-onset model ( $p$  value = 0.75). These results suggest that a high genetic risk of PD significantly increases the chance of developing PD among *LRRK2* mutation carriers.



**FIGURE 4:** Evidence of a LRRK2-CORO1C complex. (A) Immunoprecipitation (IP) analysis of lysates from HEK293FT cells transiently expressing eGFP-C1 empty vector control or eGFP-CORO1C. IP with GFP-Trap was followed with immunoblot analysis with an anti-GFP (bottom panel) or an anti-LRRK2 antibody (top panel) as indicated. Input denotes whole cell lysate material that was used for immunoprecipitation analysis. (B, C) Co-immunoprecipitation analysis of lysates from HEK293FT cells transiently co-expressing 3xflag (3FL) epitope-tagged LRRK2 with either eGFP-C1 empty vector control or eGFP-CORO1C. Epitope-tagged proteins were recovered from lysates using anti-Flag (IP: Flag) or anti-GFP (IP: GFP) antibodies, followed by immunoblot detection using anti-Flag (top panels) and anti-GFP (bottom panels) antibodies. Input denotes whole cell lysate starting material from HEK293FT cells used for immunoprecipitation analysis; +/- indicates cDNA transfections.

## Discussion

Two major unresolved questions in PD research are why some, but not all, *LRRK2* mutation carriers develop PD, and why the age-at-onset is so variable in those that do. This work represents the first GWAS study to report *LRRK2* modifiers of PD penetrance and age-at-onset. One variant on chromosome 12 reached genome-wide significance in the penetrance model (rs77395454 in an intronic region of *CORO1C*). Several loci reached suggestive significance in either the penetrance model or the age-at-onset model. One region on chromosome 3 showed suggestive associations in both models and reached genome-wide significance in penetrance model when focused on G2019S carriers only. PRS derived from a publicly available PD GWAS was a significant predictor of penetrance of PD among *LRRK2* mutation carriers.

The genome-wide significant variant, rs77395454 on chromosome 12, is located in an intronic region of *CORO1C*. Our co-immunoprecipitation experiments from HEK293 cells found LRRK2 interacted with CORO1C. In addition, there also are several proteins that are common interactors of both LRRK2 and CORO1C. Two of them, CDC42 and RAC1, have previously been validated as modifiers of *LRRK2*-mediated neurite shortening (reviewed in Boon et al 2014),<sup>50</sup> suggesting that both CORO1C and LRRK2 might have effects on the actin cytoskeleton. Furthermore, a recent APEX2 screen identified that CORO1C is physically proximate to LRRK2 in cells.<sup>51</sup> Notably, the protein expression of *Coro1c* is significantly higher in *Lrrk2* knockout mice in vivo, as shown

by proteomics and validated by Western blotting.<sup>52</sup> The accumulation of CORO1C in knockout mice might represent compensation for diminished LRRK2 function. The CORO1C protein is a member of the WD repeat protein family that has been implicated in signal transduction, gene regulation (<https://www.ncbi.nlm.nih.gov/gene/23603>). In a zebrafish model of spinal muscular atrophy, overexpression of *CORO1C* rescued the phenotype caused by *SMN* deficiency.<sup>53</sup> Using mass spectrometry, Malty et al showed that the product of *CORO1C* interacts with mitochondrial proteins associated with neurodegeneration.<sup>54</sup> Collectively, these complementary results support that CORO1C is a more likely functional interactor of LRRK2 and all of these warrant more in-depth cell and in vitro studies, including mapping the domains of LRRK2 responsible for the interaction between LRRK2 and CORO1C. However, it is possible that other genes in this region may underpin the observed association. For example, the protein product of *SSH1* regulates actin filament dynamics, which has been linked to *LRRK2* mutations.<sup>55,56</sup> *SELPLG* has been linked to neuropsychiatric disorders, such as conduct disorder.<sup>57</sup> Further studies are needed to conclusively determine the gene(s) underlying the observed association.

Multiple variants on chromosome 3 were supported by both models, although they identified different associated haplotypes. The most significant variants were rs16846845 in the penetrance model and rs150382576 in the age-at-onset model. Furthermore, rs16846845 reached genome-wide significance in G2019S only analysis for penetrance model. This region is under a known linkage peak

for PD (LOD = 2.5).<sup>58</sup> In the study by Gao et al, 2 variants (rs902432 and rs755763) had LOD scores > 2 in different analysis models.<sup>58</sup> These 2 variants are about 850 Kb upstream and 200 Kb downstream from variants identified in our study, respectively. This is consistent with our findings that top variants in either model, and variants in LD with them, were physically distinct from each other. A nearby region was also linked to PD (LOD = 3.6) in an Amish Parkinsonism pedigree linkage study performed by Lee et al.<sup>59</sup> In both Gao et al and Lee et al linkage studies, no candidate genes were nominated due to the large size of the reported linkage regions.<sup>58,59</sup> Variants that we identified are not located in any gene and the nearest gene is *RAP2B*, a member of the *RAS* oncogene family. However, its role in PD is unknown.

Rs73781088 on chromosome 5 is in the intronic region of *SEMA6A*, which is broadly expressed in the brain. This gene is associated with amyotrophic lateral sclerosis.<sup>60</sup> Rs28398294 on chromosome 8 is in the intronic region of *TNKS*, which is also broadly expressed in the brain. This region has been linked to Alzheimer's disease.<sup>61</sup> Rs141686162 on chromosome 1 is in an intergenic region near *DUSP10*, which has been associated with progressive supranuclear palsy in a recent study.<sup>62</sup> All of these findings warrant further study to investigate their potential roles in modifying the effect of *LRRK2* mutations.

We also examined the variants previously reported as *LRRK2* modifiers in other studies. Thirteen variants from 7 genes passed our QC (rs4273468 from *BST1*; rs2421947 from *DNM3*; rs1564282 from *GAK*; rs1052553, rs242562, and rs2435207 from *MAPT*; rs823144 from *PARK16*; rs11931074, rs1372525, rs181489, rs2583988, and rs356219 from *SNCA*; rs11578699 from *VAMP4*).<sup>20–32,34,35</sup> Only 4 variants from 3 genes had *p* values < 0.05: rs823144 from *PARK16* in the penetrance model (*p* value = 0.01); rs1564282 from *GAK* in both the penetrance (*p* value = 0.03) and age-at-onset models (*p* value = 7.1E-03); rs2345207 (*p* value = 5.1E-04); and rs1052553 (*p* value = 0.02) from *MAPT* in the penetrance model. Unfortunately, because some individuals in our study may have also been included in previous studies where these candidate genes were first reported, our findings do not represent independent replication. However, our results showed that previously reported variants in *BST1*, *DNM3*, *SNCA*, and *VAMP4* were not replicated, and whether they are *LRRK2* modifiers remains equivocal.

The significant effect of the PRS in the penetrance model supports the polygenic nature of the *LRRK2* modifiers (ie, there are many genetic variants each with a small effect that collectively have a significant effect on the risk of PD in *LRRK2* mutation carriers). This result is in line with the recent analysis of Iwaki et al.<sup>63</sup> In that study, a PRS was derived using

89 genomewide significant variants (some variants were also included in our PRS) identified in a PD GWAS of Nalls et al.<sup>4</sup> Iwaki et al found that the PRS was significantly associated with *LRRK2* G2019S penetrance. Potential overlap between the participants in our study and that of Iwaki et al means that the results of these studies do not represent independent replication. We did not detect a significant association in the age-at-onset model. One reason for this may be the smaller sample size (less than half of that in the penetrance model, only 776 affected from 1,879 total participants analyzed), and the resulting lack of statistical power. Another possible explanation is that the PRS was derived from a GWAS comparing PD cases and controls, and these risk-associated genes/variants are not necessarily associated with age-at-onset. Note, some participants of our study were included in the study of Nalls et al.<sup>4</sup> Although we were unable to directly check for overlapping samples and the results were potentially biased, the overlapping samples is at most 0.13% of the total sample in Nalls et al, therefore, our samples had a minimal influence on the weight estimation that was used to calculate the PRS.

There are several limitations of this study. First, despite the effort to enroll as many participants as possible, the sample size of this study still resulted in only modest statistical power. With this sample size, assuming a linear model, for a variant with MAF 3%, a change of at least 6 years of age-at-onset can be detected with 80% power at a genomewide significant level. Second, to maximize the number of eligible studies to join this collaboration, our inclusion criteria was quite minimal. Although this approach dramatically increased the sample size, many potentially important covariates were not collected and could not be adjusted for in subsequent analyses. Third, approximately 96% of our participants were G2019S carriers. However, there are carriers of other *LRRK2* mutations in the MJFF cohort. Although in a sensitivity analysis using only G2019S carriers, we observed similar effects for those top variants that we identified in both models, these mutations may have different effects that cannot be detected in the small number of carriers. Fourth, our study cohorts consisted of family participants and unrelated participants. Family history was not collected for every participant. Therefore, some unrelated individuals may be sporadic PD and have different penetrance from familial PD participants. Fifth, there was a lack of information on subjects with subtle signs of PD but who did not yet merit a diagnosis of PD. Sixth, although we included 10 PCs to adjust population stratifications, there may still exist fine-scale population stratifications that cannot be detected by those 10 PCs thus could potentially cause false positive findings. Nevertheless, we detected a genomewide significant variant. We provide experimental data to show *CORO1C* and *LRRK2* interact, and support that observation by proteomics literature. The PRS analysis suggested that there is unlikely to

be one or several single *LRRK2* modifiers, but similar to overall PD risk, penetrance of *LRRK2* mutations is affected by multiple genetic variants. Given the significant therapeutic efforts underway to develop targets for patients with PD carrying *LRRK2* mutations, further replication of these results is essential. Furthermore, the genetic variants identified in this study and the PRS evaluated in the *LRRK2* mutation carriers, may be used in the future to make personalized prevention and treatment possible.

## Acknowledgments

The authors thank the research participants from all sites who made this study possible and Tara Candido for collecting the data.

Members of the 23andMe Research Team are: Michelle Agee, Adam Auton, Robert K. Bell, Katarzyna Bryc, Sarah L. Elson, Nicholas A. Furlotte, David A. Hinds, Karen E. Huber, Aaron Kleinman, Nadia K. Litterman, Matthew H. McIntyre, Joanna L. Mountain, Elizabeth S. Noblin, Carrie A.M. Northover, Steven J. Pitts, J. Fah Sathirapongsasuti, Olga V. Sazonova, Janie F. Shelton, Suyash Shringarpure, Chao Tian, Joyce Y. Tung, Vladimir Vacic, and Catherine H. Wilson.

Genotyping services were provided by the Center for Inherited Disease Research (CIDR). CIDR is fully funded through a federal contract from the National Institutes of Health to The Johns Hopkins University, contract number HHSN2682012000081.

The authors acknowledge the Indiana University Pervasive Technology Institute for providing [HPC (Big Red II, Karst, Carbonate)] visualization, database, storage, or consulting resources that have contributed to the research results reported within this paper.

pEGFP-C1 and pEGFP-*CORO1C*<sup>53</sup> were kind gifts from Prof. Dr. Brunhilde Wirth (University of Cologne; Germany). The 3xFlag-*LRRK2* is as described.<sup>64</sup>

This work is supported by The Michael J. Fox Foundation for Parkinson's Research Grants 7984, 7984.01, 7984.02, and 8981; The Albertson Parkinson's Research Foundation; The Brookdale Foundation; The Else Kroener Fresenius Foundation; The Haworth Family Professorship in Neurodegenerative Diseases fund; The Little Family Foundation; The Parkinson's Foundation; The Sol Goldman Charitable Trust; NIH AG010124, AG062418, K02NS080915, NS036630, NS053488, NS071674, P50NS039764, P50NS062684, P50NS072187, R01NS065070, R01NS078086, R01NS096740, U54NS100693, U54NS110435, UL1TR000040, and UL1TR001873; The Department of Veterans Affairs 5I01CX001702; DOD W81XWH-17-1-0249; The DFG FOR2488; The Canadian Consortium on Neurodegeneration in Aging; The

Canadian Institutes of Health Research; The 2019 Biomarkers Across Neurodegenerative Diseases Grant Program; BAND3 18063.

## Author Contributions

T.F. and P.C. contributed to the conception and design of the study. D.L., B.A., P.F., P.C., and T.F. drafted the text and prepared the figures. D.L., B.A., P.F., T.S., J.A., R.N.A., G.W.B., D.B., S.B., A.B., K.B., L.C., M.C., S.D., V.V.D., M.F., J. Trinh, T.G., S.G., E.G., C.K., A.E.L., J.W.L., J.L., T.L., K.M., C.M., E.R.M., C.Y.M., H.M., E.M., R.H.M., K.N., L.O., H.P., D.R., E.R., M.P.R., O.A.R., A.S., R.S., B.S., C.S., W.K.S., C.T., E.T., J.E.T., D.V., J.Trojanowski, R.U., J.M.V., N.P.V., Z.K.W., C.P.Z., A.M., N.G., A.O.U., and B.F. contributed to acquisition and analysis of data. All authors reviewed and approved the submission.

## Potential Conflicts of Interest

B.A., P.F., P.C., S.D., C.Y.M., and members of the 23andMe Research Team are current or former employees of 23andMe, Inc., and hold stock or stock options in 23andMe.

## Data Availability

Aggregate-level data included in this study will be made available to qualified investigators upon request. Investigators interested in receiving 23andMe data, either alone or in combination with data from other cohorts, will need to sign a Data Transfer Agreement with 23andMe that protects 23andMe research participant privacy, and should visit <https://research.23andme.com/dataset-access/> to submit a request.

## References

1. Corti O, Lesage S, Brice A. What genetics tells us about the causes and mechanisms of Parkinson's disease. *Physiol Rev* 2011;91:1161–1218.
2. Singleton AB, Farrer MJ, Bonifati V. The genetics of Parkinson's disease: progress and therapeutic implications. *Mov Disord* 2013;28:14–23.
3. Chang D, Nalls MA, Hallgrimsdottir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. *Nat Genet* 2017;49:1511–1516.
4. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. *Lancet Neurol* 2019;18:1091–1102.
5. Alessi DR, Sammler E. *LRRK2* kinase in Parkinson's disease. *Science* 2018;360:36–37.
6. Correia Guedes L, Ferreira JJ, Rosa MM, et al. Worldwide frequency of G2019S *LRRK2* mutation in Parkinson's disease: a systematic review. *Parkinsonism Relat Disord* 2010;16:237–242.
7. Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent *LRRK2* gene mutation associated with autosomal dominant Parkinson's disease. *Lancet* 2005;365:412–415.

8. Ferreira JJ, Guedes LC, Rosa MM, et al. High prevalence of *LRRK2* mutations in familial and sporadic Parkinson's disease in Portugal. *Mov Disord* 2007;22:1194–1201.
9. Gilks WP, Abou-Sleiman PM, Gandhi S, et al. A common *LRRK2* mutation in idiopathic Parkinson's disease. *Lancet* 2005;365:415–416.
10. Lesage S, Durr A, Tazir M, et al. *LRRK2* G2019S as a cause of Parkinson's disease in North African Arabs. *N Engl J Med* 2006;354:422–423.
11. Lin CH, Tzen KY, Yu CY, et al. *LRRK2* mutation in familial Parkinson's disease in a Taiwanese population: clinical, PET, and functional studies. *J Biomed Sci* 2008;15:661–667.
12. Nichols WC, Pankratz N, Hernandez D, et al. Genetic screening for a single common *LRRK2* mutation in familial Parkinson's disease. *Lancet* 2005;365:410–412.
13. Ozelius LJ, Senthil G, Saunders-Pullman R, et al. *LRRK2* G2019S as a cause of Parkinson's disease in Ashkenazi Jews. *N Engl J Med* 2006;354:424–425.
14. Tan EK, Shen H, Tan LC, et al. The G2019S *LRRK2* mutation is uncommon in an Asian cohort of Parkinson's disease patients. *Neurosci Lett* 2005;384:327–329.
15. Hulihan MM, Ishihara-Paul L, Kachergus J, et al. *LRRK2* Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study. *Lancet Neurol* 2008;7:591–594.
16. Goldwurm S, Zini M, Mariani L, et al. Evaluation of *LRRK2* G2019S penetrance: relevance for genetic counseling in Parkinson disease. *Neurology* 2007;68:1141–1143.
17. Healy DG, Falchi M, O'Sullivan SS, et al. Phenotype, genotype, and worldwide genetic penetrance of *LRRK2*-associated Parkinson's disease: a case-control study. *Lancet Neurol* 2008;7:583–590.
18. Kachergus J, Mata IF, Hulihan M, et al. Identification of a novel *LRRK2* mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. *Am J Hum Genet* 2005;76:672–680.
19. Lee AJ, Wang Y, Alcalay RN, et al. Penetrance estimate of *LRRK2* p. G2019S mutation in individuals of non-Ashkenazi Jewish ancestry. *Mov Disord* 2017;32:1432–1438.
20. Bieri G, Brahic M, Bousset L, et al. *LRRK2* modifies alpha-syn pathology and spread in mouse models and human neurons. *Acta Neuropathol* 2019;137:961–980.
21. Cookson MR. The role of leucine-rich repeat kinase 2 (*LRRK2*) in Parkinson's disease. *Nat Rev Neurosci* 2010;11:791–797.
22. Botta-Orfila T, Ezquerro M, Pastor P, et al. Age at onset in *LRRK2*-associated PD is modified by *SNCA* variants. *J Mol Neurosci* 2012;48:245–247.
23. Cardo LF, Coto E, de Mena L, et al. A search for *SNCA* 3' UTR variants identified SNP rs356165 as a determinant of disease risk and onset age in Parkinson's disease. *J Mol Neurosci* 2012;47:425–430.
24. Dan X, Wang C, Ma J, et al. *MAPT* IVS1+124 C>G modifies risk of *LRRK2* G2385R for Parkinson's disease in Chinese individuals. *Neurobiol Aging* 2014;35:1780.e7–1780.e10.
25. Fernandez-Santiago R, Garrido A, Infante J, et al.  $\alpha$ -synuclein (*SNCA*) but not dynamin 3 (*DNM3*) influences age at onset of leucine-rich repeat kinase 2 (*LRRK2*) Parkinson's disease in Spain. *Mov Disord* 2018;33:637–641.
26. Golub Y, Berg D, Calne DB, et al. Genetic factors influencing age at onset in *LRRK2*-linked Parkinson disease. *Parkinsonism Relat Disord* 2009;15:539–541.
27. Heckman MG, Elbaz A, Soto-Ortolaza AI, et al. Protective effect of *LRRK2* p.R1398H on risk of Parkinson's disease is independent of *MAPT* and *SNCA* variants. *Neurobiol Aging* 2014;35:266.e5–266.14.
28. Trinh J, Gustavsson EK, Guella I, et al. The role of *SNCA* and *MAPT* in Parkinson disease and *LRRK2* parkinsonism in the Tunisian Arab-Berber population. *Eur J Neurol* 2014;21:e91–e92.
29. Wang C, Cai Y, Zheng Z, et al. Penetrance of *LRRK2* G2385R and R1628P is modified by common PD-associated genetic variants. *Parkinsonism Relat Disord* 2012;18:958–963.
30. Yu W, Li N, Chen L, et al. Interaction between *SNCA*, *LRRK2* and *GAK* increases susceptibility to Parkinson's disease in a Chinese population. *Mov Disord* 2015;30:5460–5461.
31. MacLeod DA, Rhinn H, Kuwahara T, et al. *RAB7L1* interacts with *LRRK2* to modify intraneuronal protein sorting and Parkinson's disease risk (vol 77, pg 425, 2013). *Neuron* 2013;79:202–203.
32. Wang L, Heckman MG, Aasly JO, et al. Evaluation of the interaction between *LRRK2* and *PARK16* loci in determining risk of Parkinson's disease: analysis of a large multicenter study. *Neurobiol Aging* 2017;49:217.e1–217.e4.
33. Latourelle JC, Hendricks AE, Pankratz N, et al. Genomewide linkage study of modifiers of *LRRK2*-related Parkinson's disease. *Mov Disord* 2011;26:2039–2044.
34. Trinh J, Gustavsson EK, Vilarino-Guell C, et al. *DNM3* and genetic modifiers of age of onset in *LRRK2* Gly2019Ser parkinsonism: a genome-wide linkage and association study. *Lancet Neurol* 2016;15:1246–1254.
35. Brown E, Blauwendraat C, Trinh J, et al. Analysis of *DNM3* and *VAMP4* as genetic modifiers of *LRRK2* Parkinson's disease. *bioRxiv* 2019: 686550.
36. Zabetian CP, Hutter CM, Yearout D, et al. *LRRK2* G2019S in families with Parkinson disease who originated from Europe and the Middle East: evidence of two distinct founding events beginning two millennia ago. *Am J Hum Genet* 2006;79:752–758.
37. Latourelle JC, Sun M, Lew MF, et al. The Gly2019Ser mutation in *LRRK2* is not fully penetrant in familial Parkinson's disease: the GenePD study. *BMC Med* 2008;6:32.
38. Di Fonzo A, Tassorelli C, De Mari M, et al. Comprehensive analysis of the *LRRK2* gene in sixty families with Parkinson's disease. *Eur J Hum Genet* 2006;14:322–331.
39. Lesage S, Ibanez P, Lohmann E, et al. G2019S *LRRK2* mutation in French and North African families with Parkinson's disease. *Ann Neurol* 2005;58:784–787.
40. Chang CC, Chow CC, Tellier LC, et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015;4:7.
41. Price AL, Patterson NJ, Plenge RM, et al. Principal components analysis corrects for stratification in genome-wide association studies. *Nat Genet* 2006;38:904–909.
42. Das S, Forer L, Schonherr S, et al. Next-generation genotype imputation service and methods. *Nat Genet* 2016;48:1284–1287.
43. Loh PR, Danecek P, Palamara PF, et al. Reference-based phasing using the haplotype reference consortium panel. *Nat Genet* 2016;48:1443–1448.
44. Follett J, Norwood SJ, Hamilton NA, et al. The *Vps35* D620N mutation linked to Parkinson's disease disrupts the cargo sorting function of retromer. *Traffic* 2014;15:230–244.
45. Cataldi S, Follett J, Fox JD, et al. Altered dopamine release and monoamine transporters in *Vps35* p.D620N knock-in mice. *NPJ Parkinsons Dis* 2018;4:27.
46. Tomkins JE, Ferrari R, Vavouraki N, et al. PINOT: an intuitive resource for integrating protein-protein interactions. *Cell Commun Signal* 2020;18:92.
47. Watanabe K, Taskesen E, van Bochoven A, Posthuma D. Functional mapping and annotation of genetic associations with FUMA. *Nat Commun* 2017;8:1826.

48. Schmitt AD, Hu M, Jung I, et al. A compendium of chromatin contact maps reveals spatially active regions in the human genome. *Cell Rep* 2016;17:2042–2059.
49. Giusti-Rodríguez P, Lu L, Yang Y, et al. Using three-dimensional regulatory chromatin interactions from adult and fetal cortex to interpret genetic results for psychiatric disorders and cognitive traits. *bioRxiv* 2019: 406330.
50. Boon JY, Dusonchet J, Trengrove C, Wolozin B. Interaction of LRRK2 with kinase and GTPase signaling cascades. *Front Mol Neurosci* 2014;7:64.
51. Bonet-Ponce L, Beilina A, Williamson CD, et al. LRRK2 mediates tubulation and vesicle sorting from membrane damaged lysosomes. *bioRxiv* 2020: 2020.01.23.917252.
52. Pellegrini L, Hauser DN, Li Y, et al. Proteomic analysis reveals coordinated alterations in protein synthesis and degradation pathways in LRRK2 knockout mice. *Hum Mol Genet* 2018;27:3257–3271.
53. Hosseinbarkoobe S, Peters M, Torres-Benito L, et al. The power of human protective modifiers: PLS3 and CORO1C unravel impaired endocytosis in spinal muscular atrophy and rescue SMA phenotype. *Am J Hum Genet* 2016;99:647–665.
54. Maly RH, Aoki H, Kumar A, et al. A map of human mitochondrial protein interactions linked to neurodegeneration reveals new mechanisms of redox homeostasis and NF-kappaB signaling. *Cell Syst* 2017;5:564–577.e12.
55. Bardai FH, Ordóñez DG, Bailey RM, et al. Lrrk promotes tau neurotoxicity through dysregulation of actin and mitochondrial dynamics. *PLoS Biol* 2018;16:e2006265.
56. Caesar M, Felk S, Aasly JO, Gillardon F. Changes in actin dynamics and F-actin structure both in synaptoneurosomes of LRRK2(R1441G) mutant mice and in primary human fibroblasts of LRRK2(G2019S) mutation carriers. *Neuroscience* 2015;284:311–324.
57. Dick DM, Aliev F, Krueger RF, et al. Genome-wide association study of conduct disorder symptomatology. *Mol Psychiatry* 2011;16: 800–808.
58. Gao X, Martin ER, Liu Y, et al. Genome-wide linkage screen in familial Parkinson disease identifies loci on chromosomes 3 and 18. *Am J Hum Genet* 2009;84:499–504.
59. Lee SL, Murdock DG, McCauley JL, et al. A genome-wide scan in an Amish pedigree with parkinsonism. *Ann Hum Genet* 2008;72: 621–629.
60. Landers JE, Melki J, Meiningner V, et al. Reduced expression of the Kinesin-Associated Protein 3 (KIFAP3) gene increases survival in sporadic amyotrophic lateral sclerosis. *Proc Natl Acad Sci U S A* 2009; 106:9004–9009.
61. Mez J, Chung J, Jun G, et al. Two novel loci, COBL and SLC10A2, for Alzheimer's disease in African Americans. *Alzheimers Dement* 2017;13:119–129.
62. Sanchez-Contreras MY, Kouri N, Cook CN, et al. Replication of progressive supranuclear palsy genome-wide association study identifies SLC10A2 and DUSP10 as new susceptibility loci. *Mol Neurodegener* 2018;13:37.
63. Iwaki H, Blauwendraat C, Makarios MB, et al. Penetrance of Parkinson's disease in LRRK2 p.G2019S carriers is modified by a polygenic risk score. *Mov Disord* 2020;35:774–780.
64. Beilina A, Bonet-Ponce L, Kumaran R, et al. The Parkinson's disease protein LRRK2 interacts with the GARP complex to promote retrograde transport to the trans-Golgi network. *Cell Rep* 2020;31: 107614.